Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
CEO Joe Jimenez told investors the firm is encouraged about the commercial prospects for CAR-T therapy. Lead drug CTL019 made Novartis' list of blockbusters in development after having been left off last year.
You may also be interested in...
As novel cell and gene therapies edge closer to the US market, reimbursement for expensive, long-lasting treatments remains uncertain. AmerisourceBergen Senior VP-Strategy & Commercialization Amy Grogg predicts the first launches will involve many different reimbursement models.
FDA's Oncologic Drugs Advisory Committee recommends 10-0 the agency approve Novartis' tisagenlecleucel (CTL019) for pediatric leukemia in a panel review that was hailed by some in the industry as historic.
UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.